Induction of Apoptosis by Apicidin, a Histone Deacetylase Inhibitor, via the Activation of Mitochondria-Dependent Caspase Cascades in Human Bcr-Abl-Positive Leukemia Cells

Clinical Cancer Research

Volumn 9, Issue 13, 2003, Pages 5018-5027

  Cheong, June Won ^a   Chong, So Young ^b   Kim, Ji Yeon ^a   Eom, Ju In ^a   Jeung, Hoi Kyung ^a   Maeng, Ho Young ^a   Lee, Seung Tae ^a   Min, Yoo Hong ^a  

^a Yonsei University College of Medicine   (South Korea)

^b CHA University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

APICIDIN; BCR ABL PROTEIN; BENZYLOXYCARBONYLASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLLEUCYLGLUTAMYLHISTIDYLASPARTYL FLUOROMETHYL KETONE; CASPASE; CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C; FAS LIGAND; FAS LIGAND DEATH RECEPTOR; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HISTONE H4; IMATINIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BCR ABL GENE; BLAST CELL CRISIS; CANCER CELL CULTURE; CELL CYCLE; CELL DEATH; CHRONIC MYELOID LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSOL; DOSE TIME EFFECT RELATION; DOWN REGULATION; DRUG ACETYLATION; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; GENE INDUCTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MITOCHONDRION; ONCOGENE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN TRANSPORT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANNEXIN A5; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BIOLOGICAL TRANSPORT; BLOTTING, WESTERN; CASPASE 3; CASPASE 8; CASPASE 9; CASPASES; CELL CYCLE; CELL LINE, TUMOR; COLORING AGENTS; CYTOCHROMES C; CYTOSOL; DNA FRAGMENTATION; DOWN-REGULATION; ENZYME ACTIVATION; ENZYME INHIBITORS; FUSION PROTEINS, BCR-ABL; GENES, ABL; HISTONE DEACETYLASES; HISTONES; HUMANS; K562 CELLS; LEUKEMIA; MITOCHONDRIA; OLIGOPEPTIDES; PEPTIDES, CYCLIC; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS;

EID: 0142157097     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Khochbin, S., Verdel, A., Lemercier, C., and Seigneurin-Berny, D. Functional significance of histone deacetylase diversity. Curr. Opin. Genet. Dev., 11: 162-166, 2001.
2. Pazin, M. J., and Kadonaga, J. T. What's up and down with histone deacetylation and transcription? Cell, 89: 325-328, 1997.
3. Wolffe, A. P. Transcriptional control. Sinful repression. Nature (Lond.), 387: 16-17, 1997.
4. Struhl, K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev., 12: 599-606, 1998.
5. Kouzarides, T. Histone acetylases and deacetylases in cell proliferation. Curr. Opin. Genet. Dev., 9: 40-48, 1999.
6. Cress, W. D., and Seto, E. Histone deacetylases, transcriptional control, and cancer. J. Cell. Physiol., 184: 1-16, 2000.
7. Vigushin, D. M., and Coombes, R. C. Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs, 13: 1-13, 2002.
8. Lin, R. J., Nagy, L., Inoue, S., Shao, W., Miller, W. J., Jr., and Evans, R. M. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature (Lond.), 391: 811-814, 1998.
9. Grignani, F., De Matteis, S., Nervi, C., Tomassoni, L., Gelmetti, V., Cioce, M., Fanelli, M., Ruthardt, M., Ferrara, F. F., Zamir, I., Seiser, C., Grignani, F., Lazar, M. A., Minucci, S., and Pelicci, P. G. Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia. Nature (Lond.), 391: 815-818, 1998.
10. Wang, J., Hoshino, T., Redner, R. L., Kajigaya, S., and Liu, J. M. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc. Natl. Acad. Sci. USA, 95: 10860-10865, 1998.
11. Wang, J., Saunthararajah, Y., Redner, R. L., and Liu, J. M. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML-ETO1 leukemia cells. Cancer Res., 59: 2766-2769, 1999.
12. Medina, V., Edmonds, B., Young, G. P., James, R., Appleton, S., and Zalewski, P. D. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/ cytochrome c-dependent pathway. Cancer Res., 57: 3697-3707, 1998.
13. Mandal, M., Adam, L., and Kumar, R. Redistribution of activated caspase-3 to the nucleus during butyric acid-induced apoptosis. Biochem. Biophys. Res. Commun., 260: 775-780, 1999.
14. Han, J. W., Ahn, S. H., Park, S. H., Wang, S. Y., Bae, G. U., Seo, D. W., Kwon, H. K., Hong, S., Lee, H. Y., Lee, Y. W., and Lee, H. W. Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res., 60: 6068-6074, 2000.
15. Juan, L. J., Shia, W. J., Chen, M. H., Yang, W. M., Seto, E., Lin, Y. S., and Wu, C. W. Histone deacetylases specifically down-regulate p53-dependent gene activation. J. Biol. Chem., 275: 20436-20443, 2000.
16. Boyes, J., Byfield, P., Nakatani, Y., and Ogryzko, V. Regulation of activity of the transcription factor GATA-1 by acetylation. Nature (Lond.), 396: 594-598, 1998.
17. Marks, P. A., Richon, V. M., and Rifkind, R. A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. (Bethesda), 92: 1210-1216, 2000.
18. Fenrick, R., and Hiebert, S. W. Role of histone deacetylase in acute leukemia. J. Cell. Biochem. Suppl., 30-31: 194-202, 1998.
19. Ferrara, F. F., Fazi, F., Bianchini, A., Padula, F., Gelmetti, V., Minucci, S., Mancini, M., Pelicci, P. G., Lo Coco, F., and Nervi, C. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res., 61: 2-7, 2000.
20. Warrell, R. P., He, L. Z., Richon, V., Calleja, E., and Pandolfi, P. P. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl. Cancer Inst. (Bethesda), 90: 1621-1625, 1998.
21. Taimi, M., Chen, Z. X., and Breitman, T. R. Potentiation of retinoic acid-induced differentiation of human acute promyclocytic leukemia NB4 cells by butyric acid, tributyrin, and hexamethylene bisacetamide. Oncol. Res., 10: 75-84, 1998.
22. Kitamura, K., Hoshi, S., Koike, M., Kiyoi, H., Saito, H., and Naoe, T. Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukemia cells with t(11;17) in combination with all-trans retinoic acid. Br. J. Haematol., 108: 696-702, 2000.
23. Amin, H. M., Saced, S., and Alkan, S. Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17). Br. J. Haematol., 115: 287-297, 2001.
24. Bernhard, D., Skvortsov, S., Tinhofer, I., Hubl, H., Greil, R., Csordas, A., and Kofler, R. Inhibition of histone deacetylase activity enhances Fas receptor-mediated apoptosis in leukemia lymphoblasts. Cell Death Differ., 8: 1014-1021, 2001.
25. Vrana, J. A., Decker, R. H., Johnson, C. R., Wang, Z., Jarvis, W. D., Richon, V. M., Ehinger, M., Fisher, P. B., and Grant, S. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/ Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene, 18: 7016-7025, 1999.
26. McGahon, A., Bissonnette, R., Schmitt, M., Cotter, K. M., Green, D. R., and Cotter, T. G. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood, 3: 1179-1187, 1994.
27. Ray, S., Bullock, G., Nunez, G., Tang, C., Ibrado, A. M., Huang, Y., and Bhalla, K. Enforced expression of Bcl-XS induces differentiation and sensitizes chronic myelogenous leukemia-blast crisis K562 cells to 1β eta-D-arabinofuranosylcytosine-mediated differentiation and apoptosis. Cell Growth Differ., 7: 1617-1623, 1996.
28. Dan, S., Naito, M., and Tsuruo, T. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR-ABL tyrosine kinase, CGP57148. Cell Death Differ., 5: 710-715, 1998.
29. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., and Sawyers, C. L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med., 344: 1031-1037, 2001.
30. Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., and Sawyers, C. L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (Wash, DC), 293: 876-880, 2001.
31. le Coutre, P., Tassi, E., Varella-Garcia, M., Barni, R., Mologni, L., Cabrita, G., Marchesi, E., Supino, R., and Gambacorti-Passerini, C. Induction of resistance to the Abelson inhibitor STI-571 in human leukemic cells through gene amplification. Blood, 95: 1758-1766, 2000.
32. Kwon, S. H., Ahn, S. H., Kim, Y. K., Bae, G. U., Yoon, J. W., Hong, S., Lee, H. Y., Lee, Y. W., Lee, H. W., and Han, J. W. Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J. Biol. Chem., 277: 2073-2080, 2002.
33. Wang, Z., Van Tuyle, G., Conrad, D., Fisher, P. B., Dent, P., and Grant. S. Dysregulation of the cyclin-dependent kinase inhibitor p21WAF/CIP1/MDA6 increases the susceptibility of human leukemia cells (U937) to 1-β-D-arabinofuranosylcytosine-mediated mitochondrial dysfunction and apoptosis, Cancer Res., 59: 1259-1267, 1999.
34. Koyama, Y., Adachi, M., Sekiya, M., Takekawa, M., and Imai, K. Histone deacetylase inhibitors suppress IL-2-mediated gene expression prior to induction of apoptosis. Blood, 96: 1490-1495, 2000.
35. Nagata, S. Apoptosis by death receptor. Cell, 88: 355-365, 1997.
36. Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K. J., Debatin, K. M., Krammer, P. H., and Peter, M. E. Two CD95 (APO-1/Fas) signaling pathways. EMBO J., 17: 1675-1687, 1998.
37. Kischkel, F. C., Hellbardt, S., Behrmann, I., Germer, M., Pawlita, M., Krammer, P. H., and Peter, M. E. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J., 14: 5579-5588, 1995.
38. Boldin, M. P., Goncharov, T. M., Goltsev, Y. V., and Wallach, D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell, 85: 803-815, 1996.
39. Budihardjo, I., Oliver, H., Lutter, M., Luo, X., and Wang, X. Biochemical pathways of caspase activation during apoptosis. Annu. Rev. Cell Dev. Biol., 15: 269-290, 1999.
40. Earnshaw, W. C., Martins, L. M., and Kaufmann, S. H. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu. Rev. Biochem., 68: 383-424, 1999.
41. Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad. M., Alnemri, E. S., and Wang, X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell, 91: 479-489, 1997.
42. Liu, X., Kim, C. N., Yang, J., Jemmerson, R., and Wang, X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell, 86: 147-157, 1996.
43. Yang, J., Liu, X., Bhalla, K., Kim, C. N., Ibrado, A. M., Cai, J., Peng, T., I., Jones, D. P., and Wang, X. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science (Wash. DC), 275: 1129-1132, 1997.
44. Kaufmann, S. H., and Earnshaw, W. C. Induction of apoptosis by cancer chemotherapy. Exp. Cell Res., 256: 42-49, 2000.
45. Goping, I. S., Gross, A., Lavoie, J. N., Nguyen, M., Jemmerson, R., Roth, K., Korsmeyer, S. J., and Shore, G. C., Regulated targeting of BAX to mitochondria. J. Cell Biol., 143: 207-215, 1998.
46. Gross, A., Jockel, J., Wei, M. C., Korsmeyer, S. J. Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J., 17: 3878-3885, 1998.
47. Park, M. T., Kang, J. A., Choi, J. A., Kang, C. M. Kim, T. H., Bae, S., Kang, S., Kim, S., Choi, W. I., Cho, C. K., Chung, H. Y., Lee, Y. S., and Lee, S. J. Phytosphingosine induces apoptotic cell death via caspase 8 activation and Bax translocation in human cancer cells. Clin. Cancer Res., 9: 878-885, 2003.
48. Keeshan, K., Cotter, T. G., and McKenna, S. L. High Bcr-Abl expression prevents the translocation of Bax and Bad to the mitochondrion. Leukemia (Baltimore), 16: 1725-1734, 2002.
49. Amarante-Mendes, G. P., Naekyung, Kim, C., Liu, L., Huang, Y., Perkins, C. L., Green, D. R., and Bhalla, K. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood. 91: 1700-1705, 1998.
50. Martin, D. A., Siegel, R. M., Zheng, L., and Lenardo, M. J. Membrane oligomerization and cleavage activates the caspase-8 (FLICE/MACHα1) death signal. J. Biol. Chem., 273: 4345-4349, 1998.
51. Fang, G., Kim, C. N., Perkins, C. L., Ramadevi, N., Winton, E., Wittmann, S., and Bhalla, K. N. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood, 96: 2246-2253, 2000.
52. Dubrez, L., Eymin, B., Sordet, O., Droin, N., Turban, A. G., and Solary, E. BCR-ABL delays apoptosis upstream of procaspase-3 activation. Blood, 91: 2415-2422, 1998.
53. Amarante-Mendes, G. P., McGahon, A. J., Nishioka, W. K., Afar, D. E., Witte, O. N., and Green, D. R. Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL. Oncogene, 16: 1383-1390, 1998.
54. Jia, L., Macey, M. G., Yin, Y., Newland, A. C., and Kelsey, S. M. Subcellular distribution and redistribution of Bcl-2 family proteins in human leukemia cells undergoing apoptosis. Blood, 93: 2353-2359, 1999.
55. Jia, L., Srinivasula, S. M., Liu, F. T., Newland, A. C., Fernandes-Alnemri, T., Alnemri, E. S., and Kelsey, S. M. Apaf-1 protein deficiency confers resistance to cytochrome c-dependent apoptosis in human leukemic cells. Blood, 98: 414-421, 2001.
56. Lee, Y. M., Kim, S. H., Kim, H. S., Son, M. J., Nakajima, H., Kwon, H. J., and Kim, K. W. Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1α activity. Biochem. Biophys. Res. Commun., 300: 241-246, 2003.
57. Tsurutani, J., Soda, H., Oka, M., Suenaga, M., Doi, S., Nakamura, Y., Nakatomi, K., Shiozawa, K., Amada, Y. Y., Kamihira, S., and Kohno, S. Antiproliferative effects of the histone deacetylase inhibitor FR901228 on small-cell lung cancer lines and drug-resistant sublines. Int. J. Cancer, 104: 238-242, 2003.
58. Nimmanapalli, R., Fuino, L., Stobaugh, C., Richon, V., and Bhalla, K. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imanitab-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood, 101: 3236-3239, 2003.